Testing ARX788 for HER2-low advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have HER2-low breast cancer (a specific lab result) that has spread or cannot be removed by surgery.
- You have had at least one prior treatment for advanced or metastatic breast cancer.
- You have a tumor that can be measured on scans or a bone lesion that can be measured.
- Your cancer has either hormone receptors (HR+) or not (HR-), and you will be in one of two groups based on that.
- You have recovered from side effects of past treatments and have adequate organ function (kidney, liver, heart, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
This trial studies a new drug called ARX788 for people with HER2-positive breast cancer that has spread or cannot be removed. It aims to see if the drug can shrink tumors and help patients live longer.
This trial tests a new targeted medicine called ARX788 for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have already tried T-DXd (a common targeted therapy) and may offer another treatment option if T-DXd stopped working.
This Phase 2 trial studies whether combining pyrotinib with ARX788 given before surgery can work better and be safe in people with HER2-positive breast cancer. It’s designed for tumors that did not respond well enough to earlier trastuzumab and pertuzumab treatment.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
Hear when a new HER2 Low Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.